Several studies demonstrated that repetitive transcranial magnetic stimulation (rTMS) is an efficacious treatment for treatment-resistant major depressive disorder (TRD). Recent metaanalyses and more recent large multicentre studies provided evidence suggesting that rTMS is indeed a promising treatment; however, its efficacy has often been shown to be modest, compared with sham stimulation. We review these lines of evidence and discuss several reasons that may explain the modest therapeutic efficacy in most of these studies, including: most involved left-sided treatment alone to the dorsolateral prefrontal cortex (DLPFC) only, which may be less optimal than applying bilateral stimulation; suboptimal methods were used to target the DLPFC (that is, the 5-cm anterior method), limiting the treatment potential of inherently a targeted form of treatment; some treatment durations were short (that is, 2 to 4 weeks); and stimulation intensity might have been insufficient by not considering coil-to-cortex distance, which has been linked to rTMS-induced antidepressant response. Future studies attempting to address the above-mentioned limitations are necessary to potentially optimize the efficacy of this already promising treatment option in TRD. Finally, it is also essential that research investigate the mechanisms of therapeutic efficacy, thus increases in understanding can be translated into enhanced treatment. For several reasons that will be reviewed, cortical excitability may represent an important mechanism, linked to the therapeutic efficacy of this disorder. Can J Psychiatry 2008; 53(9) :555-566 including MDD and schizophrenia. [4] [5] [6] In this paper, we intend to review the existing literature evaluating the efficacy of rTMS for MDD. In addition, we will review the existing neurophysiological literature in an attempt to develop our understanding of the mechanisms through which rTMS may exert its therapeutic effect for MDD. We conclude by highlighting important limitations of treatment studies to date and potential directions for future studies attempting to optimize the antidepressant efficacy of rTMS for MDD.
rTMS: A Brief Introduction
TMS is a unique experimental tool allowing researchers to noninvasively study the cortex in healthy and diseased states. 7 It has been used as an investigational tool to measure various cortical phenomena, including cortical inhibition and plasticity, a probe to explore cognitive mechanisms, 10 and as a treatment tool in illnesses such as depression and schizophrenia. 11, 12 In 1831, Michael Faraday demonstrated that a current was induced in a secondary circuit when it was brought near the primary circuit in which a time-varying current was flowing. Here, a changing electrical field produces a changing magnetic field that, consistent with Faraday's law, causes current to flow in a nearby conducting material. With TMS, electrical charge is stored in capacitors. Periodic discharge of this stored energy from the capacitor and through the conducting coil produces a time-varying electrical field. This electrical field produces a transient magnetic field that causes current to flow in a secondary conducting material, such as neurons. TMS discharge over the scalp induces a depolarization of the conducting neural tissue located just under the coil. Because intervening tissue between the coil and the cortex (that is, scalp and skull) is largely nonconducting, the magnetic field produced penetrates these tissues virtually unattenuated. The orientation and intensity of the current passing through the coil determines the type of tissue stimulated as well as the strength of that stimulation. By and large, in small figure-of-8 coils, neurons are activated in a cortical area of about 3 cm 2 and to a depth of about 2 cm. 13 In most studies, figure-of-8 coils are held over the cortex, flat, and at about 45º from the midline position, perpendicular to the central sulcus. This induces a current from posterior to anterior direction, perpendicular to descending pyramidal neurons and parallel to interneurons, which modulate pyramidal cell-firing. 14 The orientation between the coil and underlying neural tissue allows researchers to selectively activate different groups of neurons that may be key to understanding the principles mediating its therapeutic efficacy. That is, by virtue of the fact that TMS activates neurons transsynaptically 15 (that is, activation of interneurons), neuronal stimulation can selectively activate or inhibit the cortex, which, as will be discussed later, may be key to its treatment effects when applied to the cortex. rTMS involves the stimulation of the cortex by a train of magnetic pulses at frequencies between 1 to 50 Hz, in contrast to single-pulse TMS, in which the frequency of stimulation is less than 1 Hz. 16 Low-frequency rTMS (about 1 Hz) can inhibit cortical activity and has been used therapeutically to treat symptoms associated with excessive cortical activation. For example, Chen 17 demonstrated that low-frequency stimulation for a period of about 15 minutes induces a transient inhibition of the cortex. In contrast, high-frequency stimulation was shown to increase excitability. 18 More recently, we investigated the neurophysiological effects of several different rTMS frequencies (that is, 1, priming [6 Hz, followed by 1 Hz], 10, or 20 Hz) on cortical inhibition in 12 healthy subjects. 19 There was a significant lengthening of inhibitory mechanisms associated with GABA B receptor mediated inhibitory neurotransmission, with higher-stimulation frequencies (for example, 10 and 20 Hz) more effective, compared with lower-stimulation frequencies (for example, 1 Hz and priming). Therefore, these findings suggest that some of the therapeutic effects of rTMS may be coordinated through enhanced GABA-mediated inhibitory neurotransmission that is consistent with the finding that GABAergic neurotransmission is disrupted in MDD 20 and enhanced through either ECT or treatment with serotonin reuptake inhibitors. 21 Since the first published studies showing that rTMS was effective at improving mood for patients with MDD, 11,23 more than 75 studies evaluating the efficacy of rTMS for TRD have been published. As it would be beyond the scope of this paper to review all of these studies, we intend to summarize the most important in 5 broad categories: first-generation studies that have evaluated the efficacy of 10 rTMS sessions (that is, 2 weeks) for TRD; second-generation studies that have evaluated the efficacy of rTMS for more than 10 rTMS sessions; third-generation studies that evaluate the efficacy of rTMS using several novel treatment approaches (for example, bilateral rTMS); metaanalytic studies of rTMS for TRD; and future studies proposing novel methods to optimize the efficacy of rTMS for TRD. Several studies also demonstrated low-frequency rTMS (less than or equal to 1 Hz) over the right prefrontal cortex to be effective in depression. For example, in a large double-blind study of 70 depressed patients, Klein et al 28 examined the therapeutic efficacy of right prefrontal 1-Hz rTMS. Patients were randomly assigned to receive rTMS or sham rTMS. After 2 weeks of treatment, 49% of rTMS-treated patients were classified as responders (that is, a more than 50% reduction in HDRS score), whereas only 25% of patients treated with sham rTMS were responders. Other studies also demonstrated right low-frequency rTMS to be useful in depression. [29] [30] [31] Other first-generation rTMS trials in depression were equivocal or showed lack of efficacy. For example, Berman et al 32 reported only a modest reduction in depressive symptoms following a 10-day course of high-frequency rTMS to the left prefrontal cortex. This study was conducted in a double-blind placebo (that is, sham) controlled manner. Similarly, Loo et al 33 failed to find a significant difference between real and sham high-frequency rTMS to the left prefrontal cortex in 18 patients with depression following 2 weeks of treatment.
rTMS in MDD: First-Generation Studies
Other studies have also reported negligible results. 34, 35 Several explanations may account for these discrepant findings.
First, most patients included in these studies were treatmentresistant, who may represent a relatively heterogeneous subset of patients whose underlying disorder may be confounded by other comorbidities. Second, stimulation parameters including frequency, intensity, and duration vary from study to study, precluding the proper determination of these parameters to optimize the therapeutic response. Third, the concomitant use of medications in these studies obfuscates the independent effects that rTMS may have on mood symptoms, making it unclear whether improvement was related to rTMS alone, medication, or the combination of both. Fourth, no consistent method for precisely localizing the prefrontal cortex was used, and as such different cortical areas may be stimulated between subjects and between studies confounding treatment results. Kimbrell et al 36 attempted to clarify some of these factors. That is, the authors examined the possibility that a subset of depressed patients with cerebral hypometabolism would respond to high-frequency rTMS, whereas patients with cerebral hypermetabolism would respond to low-frequency rTMS, thus attempting to target treatment to potential underlying cerebral pathophysiology. Thirteen subjects participated in a 2-week randomized crossover trial in which cerebral metabolism was assessed using fluorodeoxyglucose F 18 positron emission tomography scans. They found that patients with baseline hypometabolism responded better to high-frequency rTMS stimulation, compared with patients with baseline hypermetabolism, who tended to have a better response to low-frequency rTMS. Collectively, these studies provided promising evidence that rTMS represented a potential new treatment modality for MDD. However, as the treatment effects were typically of modest therapeutic efficacy, additional studies with longer treatment durations were investigated to optimize the therapeutic efficacy of this novel form of treatment.
rTMS in MDD: Second-Generation Studies
For this review, we have found it useful to categorize studies of rTMS in depression based largely on treatment duration. That is, most rTMS studies described above typically involved 2-week treatment durations. The rationale for increasing treatment duration appears obvious when considering that 2 weeks of ECT is often insufficient in TRD, with treatments often extended to 5 weeks. In this regard, second-generation studies were completed or are currently underway using 20 or more treatments to optimize clinical efficacy. Fitzgerald et al 6 randomized 60 patients to either HFL-(that is, 10 Hz) or LFR-rTMS (that is, 1 Hz) or a sham stimulation condition (n = 20 in each group). All had TRD and failed multiple antidepressant trials (mean 5.7, SD 3.4). There were no baseline clinical or demographic differences between the 3 groups. During the double-blind phase of the study, there was clearly an antidepressant effect in both active groups that was superior to the response to sham stimulation. There was also continued improvement in both active groups across the 4 weeks of the study. After the 4 weeks of treatment, the mean change in MADRS score from baseline was 48.0%, SD 17.9% (95%CI, 15.1% to 87.5%). These results demonstrate that both HFL-and LFR-rTMS have substantial therapeutic efficacy and that clinical response appeared to require at least 20 sessions of treatment with the parameters used. More recently, Avery et al 37 compared 3 weeks of HFL-rTMS with sham rTMS in 68 patients with TRD and demonstrated that 30.6% of patients who received HFL-rTMS met criteria for therapeutic response (that is, a more than 50% decrease in symptoms on the HDRS). This was statistically superior (P < 0.05) to sham stimulation in which only 6.1% of subjects met criteria for therapeutic response. Further, the remission rate for the HFL group was 20% (that is, HDRS of less than 8) statistically superior, compared with 3% in the sham group. Perhaps the most definitive study to date evaluating the efficacy of HFL-rTMS to sham rTMS was conducted by a private TMS manufacturer (Neuronetics Pty Ltd) and involved a randomized trial of HFL-TMS (10 Hz), compared with sham rTMS, in 301 medication-free patients who had not benefited from prior antidepressant treatment. 38 This study's results demonstrated that following 6 weeks of HFL-rTMS there was a 6.3 point greater reduction in the 24-item HDRS scores relative to sham and only a 3.4 point difference relative to sham stimulation on their a priori dependant variable of interest, the 17-item HDRS (not significant). Finally, 24% of patients receiving HFL-rTMS met response criteria, compared with 12% receiving sham.
rTMS in MDD: Third-Generation Studies
Several novel stimulation approaches have been investigated in an attempt to improve rTMS treatment efficacy including bilateral rTMS. Such investigations were initiated, in part, as a result of the incontrovertible evidence that bilateral ECT is superior to unilateral ECT at similar stimulus parameters and from the evidence that HFL-and LFR-rTMS result in an antidepressant response. 6 An initial attempt at applying simultaneous bilateral high-frequency rTMS was unsuccessful. 39 Subsequently, there have been numerous trials of sequential bilateral rTMS combining HFL-and LFR-rTMS. The studies to date include: a small case series with 4 patients out of 7 classified as responders to bilateral stimulation 40 ; and a brief (5-day) treatment study comparing HFL-rTMS with bilateral rTMS and a condition with high-and low-frequency rTMS, 10 Hz and 1 Hz, respectively, both applied to left DLPFC, which showed no difference between the groups. 41 However, this study was of relatively short duration (that is, 5 consecutive days) and included a relatively small sample size (that is, n = 12 per group). Thus the failure to show group differences was likely secondary to exceptionally high response rates demonstrated by all treatment groups. In turn, this is likely to reflect the lack of a sham control (and hence nonspecific treatment factors).
In a rTMS study of somewhat larger sample size (n = 38), Hausmann et al 42 reported no significant difference in response between bilateral rTMS and HFL-rTMS; however, this study was confounded by the fact that antidepressants commenced during the course of rTMS treatment. 42 Rybak et al 43 examined the efficacy of bilateral rTMS and HFL-rTMS in 18 subjects with TRD. This study showed no significant differences between active treatment groups. However, it was relatively underpowered to show between-group differences; 6 of the 9 patients in the bilateral rTMS group and 5 of the 9 patients in the HFL-TMS group met response criteria. This high response rate may reflect that this was not a sham-controlled trial.
However, these studies were limited in several important ways. First, bilateral rTMS was not compared with unilateral and sham rTMS in a sufficiently large sample of subjects (for example, 50) needed to minimize type II error and stabilize statistical parameter estimates. 44 Also, none of the aforementioned studies were conducted for longer than 10 days and none used more than 300 LFR-rTMS pulses. In a recently published study, Fitzgerald et al 45 used bilateral rTMS (that is, 1-Hz rTMS to the right DLPFC followed by 10 Hz rTMS to the left DLPFC), compared with sham stimulation, in 50 patients with TRD (25 per group). Importantly, treatment was provided for up to 6 weeks, longer than any previously published rTMS trial. In this study, there was clearly a marked benefit of bilateral rTMS over sham stimulation.
There was a significant difference between the groups at 2 weeks (F = 1,25, df = 25.5, P < 0.001) that remained significant at all other trial time points (F = 5,44, df = 3.9, P = 0.005). Patients continued to respond across the 6 weeks of active treatment. Most critically, by study end, 13 of 25 patients in the bilateral group (more than 50%) and only 2 in the sham group met response criteria on the HDRS. Nine patients in the bilateral group (36%) and no patients in the sham group met criteria for clinical remission. A further 45% of patients in the sham group who crossed over to bilateral treatment at trial end went on to respond in a manner meeting response criteria (33% remission criteria). These response and remission rates were higher than previous shamcontrolled rTMS trials and indicate a clinically relevant level 
Metaanalyses of rTMS in MDD
There have been at least 8 metaanalyses evaluating the anti-depressant effects of left DLPFC rTMS. All but one have shown greater antidepressant effects at 2 weeks of HFL-rTMS, compared with sham; these included an analysis of 6 reports, 46 12, 47 16, 48 and 10 49 studies, and a Cochrane review of 14 studies. 50 The single negative study included only 6 reports with 91 subjects, and as such had less power than most of the other metaanalyses. 51 Despite finding differences between active-and sham-stimulation conditions, these studies reported varying effect sizes and were typically of modest clinical meaningfulness.
McNamara et al 46 conducted one of the first metaanalysis to evaluate the effectiveness of rTMS in mood disorders. A total of 16 published trials were considered, although 8 were excluded owing to the absence of a randomized controlled group and one was excluded owing to an ECT-active comparator. Among the remaining 7 controlled trials of rTMS depression, 5 involved rTMS delivered at 10 or 20 Hz to the left frontal region, one study applied 1-Hz rTMS to the right hemisphere, and in another high-and low-frequency rTMS were applied. Collectively, it was demonstrated that the rTMS was beneficial, compared with placebo, with a number needed to treat of 2.3 (95%CI, 1.6 to 4.0), in a total 81 patients. 46 Holtzhemier et al 47 included 12 studies comparing the decrease in HDRS scores achieved with rTMS and sham stimulation. In 12 studies, the weighted mean effect size was 0.81 (95%CI, 0.42 to 1.20, P < 0.001). For studies using left DLPFC stimulation (11 studies), the weighted mean effect size was 0.89 (95%CI, 0.44 to 1.35, P < 0.001). For studies using left DLPFC stimulation in a parallel-group design (7 studies), the weighted mean effect size was 0.88 (95%CI, 0.22 to 1.54, P < 0.01). No study showed a mean decrease in HDRS scores of greater than 50%, and the number of responders to rTMS (more than a 50% decrease in HDRS scores) across studies was small (13.7% with rTMS and 7.9% with sham stimulation). The authors concluded that rTMS proved to be statistically superior to sham stimulation in the treatment of depression showing a moderate-to-large effect size. However, the clinical meaningfulness of these results was brought into question owing to the modest overall change in symptoms.
Burt et al 48 Couturier et al 51 conducted a metaanalysis of rTMS treatment articles that met a priori inclusion and exclusion criteria. Six studies were included in the metaanalysis, and 13 were excluded. Reasons for excluding rTMS depression articles included the following: not using the 21-item HDRS to evaluate treatment efficacy; stimulation over areas other than the left DLPFC; lack of an intention-to-treat analysis; a treatment duration that was not 5 to 10 days; concurrent treatment with antidepressant medications; elderly subjects; and inclusion of subjects with psychotic depression. On the basis of the 6 studies chosen for analysis, Couturier concluded that rTMS was not significantly better than placebo for TRD. However, several key issues must be considered before these findings are interpreted as definitive evidence for a lack of efficacy of rTMS for TRD. First, there is growing evidence that 2 weeks (that is, 10 rTMS treatments) may be insufficient to obtain substantive clinical improvement. As such, the findings of this metaanalysis may simply imply that 10 treatments, or 2 weeks of rTMS, are ineffective for TRD. Such findings are certainly not surprising, considering that 2 weeks of ECT is often insufficient in TRD and that treatments are often extended to 4 weeks. Second, excluding studies that used different versions of the HDRS or for the concomitant use of medications, while reasonable, greatly reduced the number of studies included in this metaanalysis. As such, a total of 91 subjects in 6 studies were included, which may have limited the power of this metaanalysis to find a significant difference between active-and sham-treatment groups.
In one of the most recent metaanalyses, Gross et al 52 That is, the site, frequency, and treatment duration (for example, number of sessions varied from 10 to 16) varied considerably. Also, most studies included TRD patients; however, 2 of the selected studies did not include a TRD group. Finally, only 3 of the 5 studies used an intention-to-treat analysis. The pooled effect size of this recent metaanalysis was -0.76 (95%CI, -1.01 to -0.51), which was considerably larger than that of the earlier metaanalysis of Martin 50 (-0.35, 95%CI, -0.66 to -0.44). Gross et al 52 state that the larger effect size was due to an overall better quality of more recent studies, with improved parameters of stimulation, more rTMS sessions included, and studies using larger sample sizes.
In sum, efficacy studies evaluating HFL-rTMS to date suggest that while rTMS is therapeutically effective, the magnitude of this clinical effect remains in question. Moreover, all these metaanalyses include treatment studies with several limitations, which include: an inconsistent means of defining and quantifying treatment resistance; inconsistency regarding the maintenance, compared with the discontinuation, of medications; and diagnostic heterogeneity. Another concern that should also be raised is the link between the severity of MDD symptoms and placebo response. For example, there is evidence to suggest that, when comparing treatments for MDD, studies that include subjects with more severe depressive symptoms have lower placebo response rates (for example, a score of 25 or more on a 17-item HDRS was reported to minimize placebo response in previous medication trials 14 ) . Therefore, in studies that include subjects experiencing mild-to-moderate depressive symptoms, placebo response rates are anticipated to be as high as 50%, potentially undermining the benefits of active rTMS treatment.
Limitations of Current rTMS Trials in MDD
There are several factors that may underlie the relative modest therapeutic efficacy of rTMS studies conducted in MDD to date. First, most of these studies involved left-sided treatment alone to the DLPFC, a significant limitation when considering that when ECT is used for TRD it can be less efficacious when used unilaterally, compared with bilaterally. Second, suboptimal methods were used to target the DLPFC (that is, 5-cm anterior method) limiting the treatment potential of an inherently targeted form of treatment. 53 Third, treatment durations were typically short (that is, 2 to 4 weeks). Fourth, stimulation intensity might have been insufficient by not taking into consideration coil-to-cortex distance, which is of particular importance when considering that this parameter may contribute significantly to rTMS-induced antidepressant response. 54 Each of these limitations will be discussed in further detail below.
Variations in Targeting the DLPFC and Its Relation to Efficacy
It is possible that the modest response rates to rTMS in TRD relate to the way in which rTMS treatment is targeted over the DLPFC. Almost all studies to date have followed a standard procedure based on the earliest TMS investigations. 11, 24 This involves the localization of the motor cortical site that results in maximal activation of a peripheral hand muscle (for example, abductor pollicis brevis), and subsequently measuring 5 cm anterior along a parasagital line over the scalp surface (the 5-cm method). However, the success of the 5-cm method in targeting the DLPFC has only been evaluated in one published study. In this study, Herwig et al 53 localized the 5-cm method using a neuronavigational system and structural MRI. In only 7 of 22 subjects did the 5-cm method accurately relate to the DLPFC (defined as BA 9). In the other 15 subjects, the coil would have been located over more posterior regions, mostly over the premotor cortex. In fact, recent results suggest that this study may have overestimated even the success of the 5-cm method in localizing DLPFC. BA 9, as defined in the Brodmann system, is fairly extensive. More recent remeasurements of DLPFC, using more than the single brain employed by Brodmann, have produced a much more restricted region. For example, using coordinates for BA 9 and 46 produced in one of the studies, 55 we have reanalyzed the location of the Talairach coordinates identified by Herwig et al. 53 Our results suggest that, of the 22 patients studied, only once did the 5-cm method place the coil over BA 9, and on no occasion was it placed over BA 46. Collectively, these results suggest that traditional methods for targeting the DLPFC with rTMS may be suboptimal and may potentially explain the modest therapeutic effects of rTMS in MDD in some studies. 38
Treatment Intensity and Duration
The 2 final therapeutic considerations needing to be addressed relate to stimulation intensity and treatment duration (that is, days of stimulation). Vis-B-vis the former, previous studies have suggested that coil-to-cortex distance is an important therapeutic consideration for several reasons. First, stimulation delivered at intensities that are too high may contribute significantly to subject discomfort, increased incidence of untoward effects (such as, headaches and facial pain), or subject drop-out. Additionally, overstimulation of the cortex lessens the focality delivered by the figure-of-8 coil, which may confound treatment results. 56 By contrast, stimulation delivered at intensities that are too low may result in decreased likelihood of a lack of therapeutic efficacy. 57 As such, increasing evidence suggests that adjusting the stimulation intensity based on coil-to-cortex distance is an effective way of optimizing rTMS treatment while minimizing untoward effects. Moreover, calculating the adjusted motor threshold based on coil-to-cortex distance is a relatively minor additional layer of MRI processing when coregistering the rTMS coil to the DLPFC. Vis-B-vis treatment duration, recent literature suggests that longer treatment durations (that is, 4 to 6 weeks) are more effective than shorter treatment durations. For example, Fitzgerald et al, 6 and more recently O'Reardon et al, 38 reported that durations of 4 to 6 weeks or greater are superior to shorter treatment durations (that is, 2 to 4 weeks). In fact, when treatment durations are extended to 12 weeks, albeit in an unblinded fashion (Mark Demitrack, Neuronetics Inc, 2007 June 5, personal communication), up to an additional 20% of patients achieve a therapeutic response.
Additional Therapeutic Considerations: Mechanisms of rTMS-Induced Antidepressant Response
Several lines of evidence suggest that MDD is most commonly associated with hypoexcitability over the left prefrontal cortex and hyperexcitability over the right prefrontal cortex. The strongest evidence in support of this contention, and the reason why high-frequency (for example, 10 Hz) rTMS was initially applied to the left DLPFC and low-frequency (for example, 1 Hz) rTMS was initially applied to the right DLPFC to obtain an antidepressant response, 11, 24 is related to patients with left-sided strokes (the anatomic equivalent of hypoexcitability) who experience depression at much higher rates than in the general population and patients with right-sided strokes who experience manic symptoms at much higher rates than in the general population. Imaging studies have also demonstrated that MDD may involve dysregulation of cortical activity, with lower activity in the left DPLFC and higher activity in the right DPLFC. 58, 59 Further, rTMS treatment in MDD has often been shown to be associated with a normalization of hypoexcitability over the left prefrontal cortex and normalization of hyperexcitability over the right hemisphere, 36 consistent with the finding that rTMS applied at high frequencies increases excitability in the cortex, 60 while rTMS applied at low frequencies decreases excitability in the cortex. 17 Finally, studies have demonstrated that when 10 Hz rTMS is applied to the right DLPFC (that is, tantamount to increasing excitability in right DLPFC) dysphoric symptoms emerge. 61 However, direct evidence linking changes in excitability in DLPFC to antidepressant response is lacking. In this regard, preliminary work by Fitzgerald et al 62 demonstrated that responders to 1 Hz rTMS over the right DLPFC showed a bilateral decrease in activity in the middle frontal gyrus. In contrast, 10 Hz rTMS over the left DLPFC produced an increase in activation in the left precuneus, with responders showing increased activation in several additional regions. Moreover, response to 1 Hz right rTMS was associated with a bilateral reduction in frontal activation that was related to this form of treatment.
Single-pulse TMS can be used to evaluate excitability in the cortex. We previously assessed whether motor cortical excitability could predict the response to rTMS treatment in MDD. 63 The study included 60 TRD patients (54 MDD, 6 bipolar depression). Among these, 46 were medicated during the trial (antidepressants, mood stabilizers, and antipsychotics). We reported: a trend toward lower resting excitability in the left hemisphere in subjects with MDD; increased excitability over the right motor cortex; a significant positive correlation between increased excitability in the right hemisphere and the severity of symptoms (as measured by the BDI and Brief Psychiatric Rating Scale); and lower excitability in the left motor cortex predicted a poorer response to rTMS treatment, particularly in subjects who had a preponderance of melancholic symptoms. Collectively, these results are in keeping with the stroke literature suggesting that MDD is an illness associated with decreased excitability in the left frontal cortex and increased excitability in the right frontal cortex.
However, the above findings are limited in 2 important ways. First, results derived from imaging studies may not adequately reflect the neurophysiological processes that mediate cortical excitability. Rather, these findings may simply reflect regional cerebral blood flow. Second, the studies using TMS to evaluate excitability were limited to the motor cortex, a brain region that is less relevant to the phenomenology of MDD, compared with the DLPFC. Until recently, technical limitations prevented the ability to directly index excitability from the DLPFC. This has recently been accomplished by combining TMS with EEG, which permits direct quantification of evoked cortical activation generated by single TMS pulses. 64 For example, single-pulse TMS of the DLPFC generates cortical evoked potentials on EEG, an index of excitability in the cortex. 65 Esser et al 65 demonstrated that high-frequency rTMS, delivered over the motor cortex, resulted in an increase in excitability over the motor cortex as indexed through single-pulse TMS-induced cortical-evoked potentials. These findings are entirely consistent with what we anticipate will be the mechanism of therapeutic efficacy in TRD. That is, if high-frequency rTMS treatment in MDD is associated with increased excitability over the left DLPFC and low-frequency rTMS treatment in MDD is associated with decreased excitability over the right DLPFC then elucidating these processes may prove critical to our understanding of the therapeutic mechanisms involved in TRD. Future studies that combine TMS with EEG to evaluate cortical excitability may be used to index changes in excitability in the DLPFC as a marker of therapeutic response and may help to optimize treatment effects and elucidate the pathophysiology of this disorder.
Conclusions and Future Directions
rTMS is a promising therapy for TRD, however, its modest clinical efficacy has limited its acceptance into widespread clinical use. This modest efficacy is likely related to 4 key methodological limitations: treatment with HFL-rTMS or LFR-rTMS alone; inadequate methods of targeting the DLPFC; limited treatment durations (that is, 2 to 4 weeks); and suboptimal methods of deriving treatment intensity. Treatment studies conducted by our group of investigators suggest that applying bilateral rTMS may be substantially more effective than previous unilateral treatment approaches, although no studies directly comparing bilateral to unilateral and sham stimulation in a large randomized controlled trial have been conducted. Additionally, applying rTMS directly to the DLPFC through MRI cortical coregistration may result in enhanced therapeutic efficacy of rTMS, compared with the 5-cm method. We also anticipate that by optimizing such treatment approaches through enhanced treatment duration (that is, up to 6 weeks) and by modifying the intensity based on coil-to-cortex distance, these changes may be able to substantially enhance the efficacy of rTMS for TRD. Finally, it is critical that large treatment studies also ascertain mechanisms of therapeutic efficacy to better understand mechanisms of treatment response. Evaluating cortical excitability (for example, though positron emission tomography or by combining TMS with EEG) as a potential mechanism of therapeutic response through these novel neurophysiological approaches may be critical and potentially change the focus of rTMS application and practice, nationally and internationally, while enhancing the treatment options available for TRD. Perhaps more importantly, if such rigorous rTMS treatment approaches are not pursued then the risk that rTMS will continue to show modest efficacy and remain at the fringe of useful treatments for MDD may be perpetuated, limiting the potential of what may be a very effective therapeutic modality for TRD. The Canadian Psychiatric Association proudly supports the In Review series by providing an honorarium to the authors.
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